Skip to main content
Back to KTH start page

Publications by Arian Lundberg

Peer reviewed

Articles

[2]
[3]
D. Westaby et al., "BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity," Journal of Clinical Investigation, vol. 134, no. 18, 2024.
[4]
G. Seed et al., "Elucidating acquired PARP inhibitor resistance in advanced prostate cancer," Cancer Cell, vol. 42, no. 12, pp. 2113-2123.e4, 2024.
[7]
A. Lundberg et al., "The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer," Cancer Research, vol. 83, no. 16, pp. 2763-2774, 2023.
[8]
E. Feng et al., "Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer," Clinical Cancer Research, vol. 28, no. 24, pp. 5396-5404, 2022.
[9]
A. Lundberg et al., "Reclassifying tumour cell cycle activity in terms of its tissue of origin," npj Precision Oncology, vol. 6, no. 1, 2022.
[10]
M. Sjöström et al., "The 5-Hydroxymethylcytosine Landscape of Prostate Cancer," Cancer Research, vol. 82, no. 21, pp. 3888-3902, 2022.
[11]
A. Lundberg, B. Li and R. Li, "B cell-related gene signature and cancer immunotherapy response," British Journal of Cancer, vol. 126, no. 6, pp. 899-906, 2021.
[12]
A. Lundberg et al., "A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels," Oncogene, vol. 39, no. 32, pp. 5430-5440, 2020.
[14]
A. Lundberg et al., "Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts," Clinical Cancer Research, vol. 23, no. 24, pp. 7512-7520, 2017.
[15]
N. P. Tobin et al., "PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients," Clinical Cancer Research, vol. 23, no. 23, pp. 7225-7231, 2017.
Latest sync with DiVA:
2025-09-14 02:15:10 UTC